АНТИКОАГУЛЯНТНАЯ ТЕРАПИЯ У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ И ЦИРРОЗОМ ПЕЧЕНИ

Библиографические ссылки:

Zhang J., Johnsen S.P., Guo Y., Lip G.Y.H. Epidemiology of Atrial Fibrillation: Geographic/Ecological Risk Factors, Age, Sex, Genetics. Card Electrophysiol Clin. 2021; 13(1): 1-23https://doi.org/10.1016/j.ccep.2020.10.010

Kornej J., Börschel C.S., Benjamin E.J., Schnabel R.B. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020; 127(1): 4-20https://doi.org/10.1161/CIRCRESAHA.120.316340

Escudero-Martínez I., Morales-Caba L., Segura T. Atrial fibrillation and stroke: A review and new insights. Trends Cardiovasc Med. 2023; 33(1): 23-29https://doi.org/10.1016/j.tcm.2021.12.001

Migdady I., Russman A., Buletko A.B. Atrial Fibrillation and Ischemic Stroke: A Clinical Review. Semin Neurol. 2021; 41(4): 348-364https://doi.org/10.1055/s-0041-1726332

Lip G.Y.H., Proietti M., Potpara T., Mansour M., Savelieva I., Tse H.F., Goette A., Camm A.J., Blomstrom-Lundqvist C., Gupta D., Boriani G. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace. 2023; 25(9): euad226https://doi.org/10.1093/europace/euad226

Jame S., Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart. 2020; 106(1): 10-17https://doi.org/10.1136/heartjnl-2019-314898

Smith A., Baumgartner K., Bositis C. Cirrhosis: Diagnosis and Management. Am Fam Physician. 2019; 100(12): 759-770. PMID: 31845776

Ginès P., Krag A., Abraldes J.G., Solà E., Fabrellas N., Kamath P.S. Liver cirrhosis. Lancet. 2021; 398(10308): 1359-1376https://doi.org/10.1016/S0140-6736(21)01374-X

Huang D.Q., Terrault N.A., Tacke F., Gluud L.L., Arrese M., Bugianesi E., Loomba R. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023; 20(6): 388-398https://doi.org/10.1038/s41575-023-00759-2

Moon A.M., Singal A.G., Tapper E.B. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020; 18(12): 2650-2666https://doi.org/10.1016/j.cgh.2019.07.060

Northup P., Reutemann B. Management of Coagulation and Anticoagulation in Liver Transplantation Candidates. Liver Transplantation. 2018; 24(8): 1119-32https://doi.org/10.1002/lt.25198

Fuentes A., Gordon‐Burroughs S., Hall J.B., Putney D.R., Monsour H.P. Jr. Comparison of anti‐Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis. Ther Drug Monit. 2015; 37: 40-44https://doi.org/10.1097/FTD.0000000000000105

Rodriguez‐Castro K.I., Simioni P., Burra P., Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int. 2012; 32: 1465-1476https://doi.org/10.1111/j.1478-3231.2012.02839.x

Vandenberk B., Altieri M.H., Liu H., Raj S.R., Lee S.S. Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension. Aliment Pharmacol Ther. 2023; 57(3): 290-303https://doi.org/10.1111/apt.17368

Chokesuwattanaskul R., Thongprayoon C., Bathini T., O'Corragain O.A., Sharma K., Preechawat S., Wijarnpreecha K., Kröner P.T., Ungprasert P., Cheungpasitporn W. Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis. Eur J Gastroenterol Hepatol. 2019; 31(4): 514-519https://doi.org/10.1097/MEG.0000000000001315

Lee H., Choi E.K., Rhee T.M., Lee S.R., Lim W.H., Kang S.H., Han K.D., Cha M.J., Oh S. Cirrhosis is a risk factor for atrial fibrillation: A nationwide, population-based study. Liver Int. 2017; 37(11): 1660-1667https://doi.org/10.1111/liv.13459

B Riahi E., Adelborg K., Pedersen L., Kristensen S.R., Hansen A.T., Sørensen H.T. Atrial fibrillation, liver cirrhosis, thrombosis, and bleeding: A Danish population-based cohort study. Res Pract Thromb Haemost. 2022; 6(2): e12668https://doi.org/10.1002/rth2.12668

Darrat Y.H., Smer A., Elayi C.S., Morales G.X., Alqahtani F., Alkhouli M., Catanzaro J., Shah J., Salih M. Mortality and morbidity in patients with atrial fibrillation and liver cirrhosis. World J Cardiol. 2020; 12(7): 342-350https://doi.org/10.4330/wjc.v12.i7.342

Luo Y., Wu B., Wu Y., Peng L., Li Z., Zhu J., Su Z., Liu J., Li S., Chong Y. Atrial fibrillation increases inpatient and 4-year all-cause mortality in critically ill patients with liver cirrhosis. Ann Transl Med. 2021; 9(15): 1239https://doi.org/10.21037/atm-21-3111

Simon T.G., Schneeweiss S., Singer D.E., Sreedhara S.K., Lin K.J. Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2023; 12(3): e026863https://doi.org/10.1161/JAHA.122.026863

Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators; Singer D.E., Hughes R.A., Gress D.R., Sheehan M.A., Oertel L.B., Maraventano S.W., Blewett D.R., Rosner B., Kistler J.P. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990; 323(22): 1505-11https://doi.org/10.1056/NEJM199011293232201

Petersen P., Boysen G., Godtfredsen J., Andersen E.D., Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989; 1(8631): 175-9https://doi.org/10.1016/s0140-6736(89)91200-2

Lai W., Lu S.C., Li G.Y., Li C.Y., Wu J.S., Guo Q.L., Wang M.L., Li N. Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization. World J Gastroenterol. 2012; 18(26): 3443-50https://doi.org/10.3748/wjg.v18.i26.3443

Werner K.T., Sando S., Carey E.J., Vargas H.E., Byrne T.J., Douglas D.D., Harrison M.E., Rakela J., Aqel B.A. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013; 58(6): 1776-80https://doi.org/10.1007/s10620-012-2548-y

Chen H., Liu L., Qi X., He C., Wu F., Fan D., Han G. Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2016; 28(1): 82-9https://doi.org/10.1097/MEG.0000000000000482

Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., Lewis B.S., Darius H., Diener H.C., Joyner C.D., Wallentin L.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-51https://doi.org/10.1056/NEJMoa0905561

Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A., Califf R.M.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891https://doi.org/10.1056/NEJMoa1009638

Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., Al‐Khalidi H.R., Ansell J., Atar D., Avezum A., Bahit M.C., Diaz R., Easton J.D., Ezekowitz J.A., Flaker G., Garcia D., Geraldes M., Gersh B.J., Golitsyn S., Goto S., Hermosillo A.G., Hohnloser S.H., Horowitz J., Mohan P., Jansky P., Lewis B.S., Lopez‐Sendon J.L., Pais P., Parkhomenko A., Verheugt F.W., Zhu J., Wallentin L.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992https://doi.org/10.1056/NEJMoa1107039

Giugliano R.P., Ruff C.T., Braunwald E., Murphy S.A., Wiviott S.D., Halperin J.L., Waldo A.L., Ezekowitz M.D., Weitz J.I., Špinar J., Ruzyllo W., Ruda M., Koretsune Y., Betcher J., Shi M., Grip L.T., Patel S.P., Patel I., Hanyok J.J., Mercuri M., Antman E.M.; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22): 2093-104https://doi.org/10.1056/NEJMoa1310907

Qamar A., Vaduganathan M., Greenberger N.J., Giugliano R.P. Oral Anticoagulation in Patients With Liver Disease. J Am Coll Cardiol. 2018; 71(19): 2162-2175https://doi.org/10.1016/j.jacc.2018.03.023

Hindley B., Lip G.Y.H, McCloskey A.P., Penson P.E. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. Expert Opin Drug Metab Toxicol. 2023; 19(12): 911-923https://doi.org/10.1080/17425255.2023.2287472

Serper M., Weinberg E.M., Cohen J.B., Reese P.P., Taddei T.H., Kaplan D.E. Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. Hepatology. 2021; 73(1): 219-232https://doi.org/10.1002/hep.31264

Lee H.F., Chan Y.H., Chang S.H., Tu H.T., Chen S.W., Yeh Y.H., Wu L.S., Kuo C.F., Kuo C.T., See L.C. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2019; 8(5): e011112https://doi.org/10.1161/JAHA.118.011112

Hu T., Li Y.H., Han W.Q., Maduray K., Chen T.S., Hao L., Zhong J.Q. Direct Oral Anticoagulants versus Vitamin K Antagonists in Cirrhotic Patients with Atrial Fibrillation: Update of Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2023; 23(6): 683-694https://doi.org/10.1007/s40256-023-00598-1

Zhao Y., Zhu L., Yang Y., Gao H., Zhang R. Safety of direct oral anticoagulants in patients with liver disease: a systematic review and meta-analysis. Acta Clin Belg. 2023; 78(3): 234-244https://doi.org/10.1080/17843286.2022.2108259

Nisly S.A., Mihm A.E., Gillette C., Davis K.A., Tillett J. Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis. J Thromb Thrombolysis. 2021; 52(3): 817-827https://doi.org/10.1007/s11239-021-02424-4

Fu Y., Zhu W., Zhou Y., Chen H., Yan L., He W. Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review. Am J Cardiovasc Drugs. 2020; 20(2): 139-147https://doi.org/10.1007/s40256-019-00369-x

Lee Z.Y., Suah B.H., Teo Y.H., Teo Y.N., Syn N.L.X., Yeo T.C., Wong R.C.C., Chai P., Wong Y.J., Ho J.S.Y., Leow A.S., Yeo L.L.L., Tan B.Y.Q., Sia C.H. Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Patients with Atrial Fibrillation and Concomitant Liver Cirrhosis: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2022; 22(2): 157-165https://doi.org/10.1007/s40256-021-00482-w

Huang Z.C., Li C.Q., Liu X.Y., Cao Z.C., Jia H.Y., Dong Y., Liu T.L., Sun J.J. Efficacy and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Liver Disease: a Meta-Analysis and Systematic Review. Cardiovasc Drugs Ther. 2021; 35(6): 1205-1215https://doi.org/10.1007/s10557-020-07065-y

Balcı K.G., Balcı M.M., Canpolat U., Şen F., Akboğa M.K., Süleymanoğlu M., Kuyumcu S., Maden O., Selçuk H., Selçuk M.T. Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. Anatol J Cardiol. 2016; 16(7): 474-481https://doi.org/10.5152/AnatolJCardiol.2015.6334

Lee S.J., Uhm J.S., Kim J.Y., Pak H.N., Lee M.H., Joung B. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. Int J Cardiol. 2015; 180: 185-91https://doi.org/10.1016/j.ijcard.2014.11.183

Coons E.M., Staubes B.A., Casey A.L., Elagizi-Youssef S.A., Mohammed A.E., Sharma N., Kline E.R. Direct Oral Anticoagulants Versus Warfarin for Treatment of Thrombosis or Atrial Fibrillation in Patients With Cirrhosis: A Retrospective Cohort Study. Ann Pharmacother. 2022; 56(5): 533-540https://doi.org/10.1177/10600280211025050

Oldham M., Palkimas S., Hedrick A. Safety and Efficacy of Direct Oral Anticoagulants in Patients With Moderate to Severe Cirrhosis. Ann Pharmacother. 2022; 56(7): 782-790https://doi.org/10.1177/10600280211047433

Jarboe L., Dadlani A., Bandikatla S., Wade R., Barve A. Drug Use Evaluation of Direct Oral Anticoagulants (DOACs) in Patients With Advanced Cirrhosis. Cureus. 2022; 14(4): e24029https://doi.org/10.7759/cureus.24029

Yoo S.Y., Kim E., Nam G.B., Lee D., Shim J.H., Kim K.M., Lim Y.S., Lee H.C., Chung Y.H., Lee Y.S., Choi J. Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation. Korean J Intern Med. 2022; 37(3): 555-566https://doi.org/10.3904/kjim.2020.622

Sasso R., Rockey D.C. Anticoagulation Therapy in Patients with Liver Cirrhosis is Associated With an Increased Risk of Variceal Hemorrhage. Am J Med. 2019; 132(6): 758-766https://doi.org/10.1016/j.amjmed.2019.01.006

Diesveld M.M.E., Pijnenburg D.W.M.J., Weersink R.A., Barzel I., Drenth J.P.H., Lisman T., Metselaar H.J., Monster-Simons M.H., Mulder M.B., Okel E., Taxis K., Borgsteede S.D. Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data. Eur J Clin Pharmacol. 2024. Advance online publicationhttps://doi.org/10.1007/s00228-024-03648-y